Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses novel therapies that can be given in acute myeloid leukemia (AML) post-transplant to reduce the risk of relapse.
Maintenance therapy strategies to reduce relapse in AML
